Digital Access to genomic surveillance: Open science and public heal... The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
News BioMarin snaps up Alesta's lead asset for $275M BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
